In Vitro and In Vivo Synergistic Therapeutic Effect of Cisplatin with Human Papillomavirus16 E6/E7 CRISPR/Cas9 on Cervical Cancer Cell Line
Open Access
- 28 October 2016
- journal article
- Published by Elsevier BV in Translational Oncology
- Vol. 9 (6), 498-504
- https://doi.org/10.1016/j.tranon.2016.10.002
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Plasmid-based E6-specific siRNA and co-expression of wild-type p53 suppresses the growth of cervical cancer in vitro and in vivoCancer Letters, 2013
- Generation of gene-modified mice via Cas9/RNA-mediated gene targetingCell Research, 2013
- Papillomaviruses in the causation of human cancers — a brief historical accountVirology, 2009
- Strategies for silencing human disease using RNA interferenceNature Reviews Genetics, 2007
- Requirement of E7 oncoprotein for viability of HeLa cellsMicrobes and Infection, 2006
- Carcinogenicity of human papillomavirusesThe Lancet Oncology, 2005
- Escape of p53 protein from E6‐mediated degradation in HeLa cells after cisplatin therapyInternational Journal of Cancer, 2002
- Concurrent Chemotherapy and Pelvic Radiation Therapy Compared With Pelvic Radiation Therapy Alone as Adjuvant Therapy After Radical Surgery in High-Risk Early-Stage Cancer of the CervixJournal of Clinical Oncology, 2000
- High Levels of Foreign Gene Expression in Hepatocytes after Tail Vein Injections of Naked Plasmid DNAHuman Gene Therapy, 1999
- Cellular responses of HPV-positive cancer cells to genotoxic anti-cancer agents: Repression ofE6/E7-oncogene expression and induction of apoptosisInternational Journal of Cancer, 1996